U.S. COPD Market - Therapeutic Overview and Patient OutlookFrost & SullivanJune 18, 2007 80 Pages - SKU: MC1505985 |
| Countries covered: United States The Frost & Sullivan research service titled U.S. COPD Market: Therapeutic Overview and Patient Outlook provides insight into marketed products, patient forecasts, and selected therapeutic approaches that are outside of current marketed areas. In this research, Frost & Sullivan's expert analysts thoroughly examine the following markets: bronchodilators, anti-inflammatories, combination therapies, and novel therapeutic approaches. COPD remains one of the Leading Under-diagnosed Diseases Chronic obstructive pulmonary disease or COPD is a slow progressing disease, characterized by airflow obstruction, which consists of both chronic bronchitis and emphysema. The disease remains incurable and current treatments are only able to help relieve symptoms and slow the progression of the disease rather than reverse any lung damage. While around 13.6 million Americans have been diagnosed with this disease, it is estimated that an additional 15 million Americans have the disease but remain undiagnosed. This makes COPD one of the leading under-diagnosed diseases in the U.S. According to the National Institute of Health, COPD is currently the fourth-leading cause of death in the U.S. and is expected to ascend to the third position by 2020. Smoking is the largest contributing factor to the development of COPD. Although the number of adult smokers decreased in the last decade, these numbers seem to have leveled off with the smoking rate staying virtually the same. "Furthermore, with an estimated 45 million current smokers and 45.9 million former smokers in the U.S. the COPD patient population is expected to expand," notes the analyst of this research service. "This could increase the number of people requiring treatment for this disease and subsequently maintain positive revenue growth." Poor Patient Compliance Restraining Market Growth One of the major obstacles in the expansion of the U.S. COPD market is the high rate of patient noncompliance. COPD is cited as having the fourth-highest rate of patient noncompliance. It is estimated that the prescription compliance rate for these patients is under 50 percent, and many experts believe that actual compliance rates are much lower. For example, in The Lung Health Study, it was determined that for bronchodilators, compliance as measured by canister weight was actually 10 percent lower then reported compliance rates. Another study found that compliance rates for patient use of inhaled corticosteroids were as low as 18 percent. Moreover, medications used to treat COPD come with side-effects, which often discourage patients from long-term use of these products. Side-effects for COPD medications are magnified with multiple medications and this amplifies the problem as the typical COPD patient is prescribed several different medications. Developing drugs that required less frequent dosing could go a long way in addressing compliance concerns. The success of products such as Spiriva and Advair that require less frequent dosing only reconfirms the need for more convenient treatment options. "Going forward, the number of Americans diagnosed with COPD is expected to increase by 34.5 percent from 13.6 million to 18.4 million in 2013," says the analyst. "This increase can be attributed to several factors including the increased growth in the older age segments of the population, the high number of current and former smokers, and an increase in screening for COPD." |
More United States Respiratory/Pulmonary Reports
Epidemiology: COPD - Aging population and stable smoking rates to raise case numbers by
Datamonitor
Introduction In 2010, Datamonitor estimates that there were about 69.5 million total prevalent cases of chronic obstructive pulmonary disease (COPD) in people aged over 40 in ...
Cystic Fibrosis by
Global Industry Analysts
This report analyzes the US market for Cystic Fibrosis in Millions of US$. Annual estimates and forecasts are provided for the period of 2007 through ...
U.S. Sleep Apnea Diagnostic and Therapeutic Devices Markets by
Frost & Sullivan
This research service analyzes market trends in the U.S. sleep apnea diagnostic and therapeutic devices market since 2005, predicts future changes in market measurements through ...
Nosocomial Infections: Market Impact on Diagnostics and Therapeutics: (MRSA, HAP, C. diff and other Hospital Acquired Infections) by
Kalorama Information
A nosocomial, or hospital-acquired, infection is a new infection that is usually defined as an infection that is identified at least forty-eight to seventy-two hours ...
The U.S. Sleep Market by
Marketdata Enterprises Inc.
Of a total population of 305 million Americans, 58% are estimated to experience insomnia symptoms or sleep disorders. Companies across America are trying to sell ...
See all reports like this >>
More United States Reports
e-Discovery Software Publishing in the US - Industry Market Research Report by
IBISWorld
e-Discovery Software Publishing in the US Finding growth : Electronic discovery (more often known as e-discovery) refers to a data search, location and securing process for use ...
D&B Country RiskLine Report: The United States of America by
Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...
D&B Country Report: The United States of America by
Dun & Bradstreet Inc.
D&B Country Report. Comprehensive information for evaluating risks and opportunities when trading or investing in this country. Providing critical information and analysis on ...
Country Report United States January 2011 by
Economist Intelligence Unit
Country Reports analyse political and economic trends in featured countries. They show you exactly how national, regional and global events will affect your business in ...
Coal - US - a snapshot (2010) by
Mintel - Snapshots
Coal in US by Mintel Global Market Navigator provides you with annual year-end market size data, most recently updated in 2010. This market covers consumption ...
See all reports like this >>
Related Markets
- Diseases & Conditions
- Asthma
- Medical Devices
- Respiratory Devices
- Therapeutic Area
- Respiratory/Pulmonary
Respiratory/Pulmonary Reports
- Triple Analysis: Lung Cancer, Protein Kinase Inhibitors and Peptides
- Triple Analysis: Lung Cancer, Protein Kinase Inhibitors and Antibodies
- Triple Analysis: Lung Cancer, Angiogenesis and Protein Kinase Inhibitors
- Triple Analysis: Breast Cancer, Lung Cancer and Protein Kinase Inhibitors
- Viral Respiratory Tract Infection Global Clinical Trials Review, H1, 2012
